Mark Ranalli is an Oncology physician affiliated with Nationwide Children's Hospital. OpenAlex indexes 66 publications with 1,244 citations (h-index 19); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Sponsor: New Approaches to Neuroblastoma Therapy Consortium
- NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Sponsor: Nationwide Children's Hospital
- MIBG Therapy for Patients With MIBG Avid Tumors
Sponsor: Nationwide Children's Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Similar KOLs
Other experts from the same institution or the same specialty.
Maryam Fouladi, MD
Nationwide Children's Hospital
Toshiharu Shinoka, MD
Nationwide Children's Hospital
William Smoyer, MD
Nationwide Children's Hospital
Mark Galantowicz, MD
Nationwide Children's Hospital
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”